The producer of contrast Guerbet began to use IBM Watson for diagnosis of a prostate cancer

In the middle of September, 2019 the producer of contrast Guerbet signed the second agreement on cooperation with IBM Watson Health. This time the companies integrated in development of the AI tool which will help clinical physicians to reveal, segment, characterize and trace a prostate cancer.

The prostate cancer became a global problem of public health care because of aging of the population, but the correct tools will allow doctors quicker and more precisely to diagnose different cases. The main diagnostic problem at a prostate cancer consists in recognition of the tumoral defeats requiring fast treatment, and those which require only active observation. Therefore results of treatment of the patient depend on speed and the accuracy of diagnostics, and with this AI tool area can significantly help specialists.

Guerbet signed the second agreement on cooperation with IBM Watson Health which will help for diagnosis of a prostate cancer

The general manager by techniques of visualization and oncology of IBM Watson Health Anne Le Grand noted that the new AI tool for detection of a prostate cancer will be considered as decision making support system which uses the analysis of images of Watson for profound diagnostics, potentially will lower number of unnecessary biopsies and will be able to offer the most suitable therapeutic strategy for each patient.

Guerbet and IBM for the first time combined the efforts in July, 2018 for development of an AI system for diagnostics and monitoring of patients with liver cancer. The companies intend to use achievements of early cooperation in work on the second project. According to the companies, the developed AI tool should be compatible to the majority of the systems of visualization of PACS (Picture Archiving and Communication System) that considerably will simplify its direct integration into workflows of health workers.^[1]

Notes